Dispersible Concentrate Lipospheres for the Improved Bioavailability of Pharmacologic Agents (Yissum)

code: 12-2006-606

Abraham DOMB, HUJI, School of Pharmacy, Pharmacology

Nanoformulation makes a wide range of drugs more stable, controllable with lower preparation costs

Categories	**Nanodispersion, pharmacology, liposphere, liphophilic drug, concentrated pre-dispersion, amphotericin B**
Development Stage	**Concept proven with cyclosporine and amphotericin B**
Patent Status	**Patent pending**
Market Size	**$60B**

Highlights

- **Replaces highly toxic, complicated and expensive infusion formulations**
- **Easy preparation and scale-up**
- **Works with oral, topical and IV pharmacological agents**
- **Extended release from a few hours to several days of entrapped drug after a single injection**

Our Innovation

- **Developed concentrated nano-formulations for improved bioavailability of lipophilic drugs**
- **Better physical stability**
- **Low cost of ingredients**
- **High dispersability in an aqueous medium**
- **High entrapment of hydrophobic drugs**

The Opportunity

- **Alternative formulations for existing marketed drugs for faster absorption or clear soft gelatin capsules**
- **Provides controlled delivery of a wide range of drugs including but not exclusive to anti-inflammatory compounds, local anesthetics, antibiotics, anticancer agents, vaccines, adjuvants, and peptides**
- **Allows oral formulation of drugs previously only administered IV or by infusion**

Contact for more information:

Shoshana Keynan ✉, VP, Head of Business Development, Healthcare, +972-2-6586683

Yissum Research Development Company of the Hebrew University of Jerusalem
Hi-Tech Park, Edmond J. Safra Campus, Givat-Ram, Jerusalem P.O. Box 39135, Jerusalem 91390
Israel Telephone: 972-2-658-6688, Fax: 972-2-658-6689